

Patient: _____

Hospital: _____

City, Province: _____

Hospital 24-hour contact name and number:

This patient has been administered LUTATHERA®

Procedure date and time: _____

Activity administered: _____



A Novartis Company



LUTATHERA[®]

(lutetium ¹⁷⁷Lu oxodotreotide)

Sterile Solution for intravenous infusion

Lu177-1020-22E

DIN: 02484552

Visit www.lutathera.ca for more information

